Indication for Surgery in Small-cell Carcinoma of the Lung
Indication for Surgery in Small-cell Carcinoma of the Lung
复制标题
小细胞肺癌的手术指征
DOI：
10.1055/s-2007-1020145
复制
发表时间：
1992
期刊：
影响因子：
--
通讯作者：
W. Matthiesen
中科院分区：
文献类型：
--
作者：
D. Kaiser;A. Fritzsche;W. Matthiesen
虽然化学治疗剂的发展导致了肺小细胞癌治疗的进展，但局部复发的数量仍然很高。手术治疗I期和II期肿瘤，然后进行术后化疗是治疗的选择，并已在世界范围内被接受。在IIIa期肿瘤中，特别是在T1-3 N2期，我们采用多模式治疗方案，包括新辅助化疗（术前3个周期）和手术以及术后化疗和纵隔放疗，在预计的3年生存期中获得了良好的结果。I期肿瘤的3年生存率为67%，II期为42%，而我们的多模式治疗方案在IIIa期肿瘤中为38%。
While the development of chemotherapeutic agents has lead to progress in the treatment of small-cell carcinomas of the lung, the number of local recurrences still remains high. Surgery in tumors stage I and II followed by postoperative chemotherapy is the treatment of choice and has been accepted worldwide. In tumors stage IIIa, especially in T1-3 N2 we obtained good results in the projected 3-year survival using a multimodality therapeutic regime consisting of neoadjuvant chemotherapy (3 cycles preoperative) and surgery as well as postoperative chemotherapy and irradiation of the mediastinum. Projected 3-year survival was 67% in stage I tumors, 42% in stage II and with our multimodality therapeutic regime 38% in stage III a tumors.